Phase 1b Randomized Trial and Follow-Up Study in Uganda of the Blood-Stage Malaria Vaccine Candidate BK-SE36

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Palacpac, Nirianne Marie Q ^a,b   Ntege, Edward ^c   Yeka, Adoke ^c,d   Balikagala, Betty ^c   Suzuki, Nahoko ^b   Shirai, Hiroki ^b   Yagi, Masanori ^a   Ito, Kazuya ^e,f   Fukushima, Wakaba ^e   Hirota, Yoshio ^e   Nsereko, Christopher ^g,j   Okada, Takuya ^b   Kanoi, Bernard N ^c   Tetsutani, Kohhei ^b,h   Arisue, Nobuko ^a   Itagaki, Sawako ^a   Tougan, Takahiro ^a   Ishii, Ken J ^h,i   Ueda, Shigeharu ^b   Egwang, Thomas G ^c   Horii, Toshihiro ^a   more..

^a OSAKA UNIVERSITY   (Japan)

^b The Research Foundation for Microbial Diseases of Osaka University   (Japan)

^c Med Biotech Laboratories Uganda   (Uganda)

^d MAKERERE UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Uganda)

^e Osaka Prefecture University   (Japan)

^f Medical Co LTA Clinical Pharmacology Center   (Japan)

^g Lira Medical Centre   (Uganda)

^h NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

ⁱ OSAKA UNIVERSITY   (Japan)

^j KAMPALA INTERNATIONAL UNIVERSITY   (Uganda)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BK SE 36; MALARIA VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; APPLICATION SITE ERYTHEMA; ARTICLE; BLOOD PRESSURE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; GASTRITIS; HUMAN; HYPEREMIA; HYPERPIGMENTATION; IMMUNOGENICITY; INFECTION RISK; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALARIA FALCIPARUM; MALE; OUTCOME ASSESSMENT; PARASITE INCIDENCE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROCONVERSION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN REDNESS; UGANDA; VACCINATION;

ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIFE CYCLE STAGES; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; TREATMENT OUTCOME; UGANDA; VACCINATION; YOUNG ADULT;

PLASMODIUM FALCIPARUM;

EID: 84878407002     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064073     Document Type: Article

References (30)

1. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, et al. (2012) Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379: 413-431.
2. Greenwood BM, Targett GA, (2011) Malaria vaccines and the new malaria agenda. Clin Microbiol Infect 17: 1600-1607.
3. Yeka A, Gasasira A, Mpimbaza A, Achan J, Nankabirwa J, et al. (2012) Malaria in Uganda: Challenges to control on the long road to elimination: I. Epidemiology and current control efforts. Acta Trop 121: 184-195.
4. Schwartz L, Brown GV, Genton B, Moorthy VS, (2012) A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J 11: 11.
5. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, et al. (2011) First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 365: 1863-1875.
6. The RTS, S Clinical Trials Partnership, (2012) A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. N Engl J Med 367: 2284-2295.
7. Richards JS, Beeson JG, (2009) The future for blood-stage vaccines against malaria. Immunol. Cell Biol 87: 377-390.
8. Crompton PD, Pierce SK, Miller LH, (2010) Advances and challenges in malaria vaccine development. J Clin Invest 120: 4168-4178.
9. malERA Consultative Group on Vaccines (2011) A research agenda for malaria eradication: vaccines. PLoS Med 8: e1000398.
10. Li J, Mitamura T, Fox BA, Bzik DJ, Horii T, (2002) Differential localization of processed fragments of Plasmodium falciparum serine repeat antigen and further processing of its N-terminal 47 kDa fragment. Parasitol Int 51: 343-352.
11. Aoki S, Li J, Itagaki S, Okech BA, Egwang TG, et al. (2002) Serine repeat antigen (SERA5) is predominantly expressed among the SERA multigene family of Plasmodium falciparum, and the acquired antibody titers correlate with serum inhibition of the parasite growth. J Biol Chem 277: 47533-47540.
12. Miller SK, Good RT, Drew DR, Delorenzi M, Sanders PR, et al. (2002) A subset of Plasmodium falciparum SERA genes are expressed and appear to play an important role in the erythrocytic cycle. J Biol Chem 277: 47524-47532.
13. Yeoh S, O'Donnell RA, Koussis K, Dluzewski AR, Ansell KH, et al. (2007) Subcellular discharge of a serine protease mediates release of invasive malaria parasites from host erythrocytes. Cell 131: 1072-1083.
14. Horii T, Shirai H, Jie L, Ishii KJ, Palacpac NQ, et al. (2010) Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36. Parasitol Int 59: 380-386.
15. Palacpac NM, Arisue N, Tougan T, Ishii KJ, Horii T, (2011) Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate. Vaccine 29: 5837-5845.
16. Tanabe K, Arisue N, Palacpac NM, Yagi M, Tougan T, et al. (2012) Geographic differentiation of polymorphism in the Plasmodium falciparum malaria vaccine candidate gene SERA5. Vaccine 30: 1583-1593.
17. Okello PE, Van Bortel W, Byaruhanga AM, Correwyn A, Roelants P, et al. (2006) Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg 75: 219-225.
18. Proietti C, Pettinato DD, Kanoi BN, Ntege E, Crisanti A, et al. (2011) Continuing intense malaria transmission in northern Uganda. Am J Trop Med Hyg 84: 830-837.
19. Njama-Meya D, Kamya MR, Dorsey G, (2004) Asymptomatic parasitaemia as a risk factor for symptomatic malaria in a cohort of Ugandan children. Trop Med Int Health 9: 862-868.
20. O'Meara WP, Hall BF, McKenzie FE, (2007) Malaria vaccine efficacy: the difficulty of detecting and diagnosing malaria. Malar J 6: 36.
21. Pocock SJ, Clayton TC, Altman DG, (2002) Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 359: 1686-1689.
22. Sirima SB, Tiono AB, Ouédraogo A, Diarra A, Ouédraogo AL, et al. (2009) Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children. PLoS ONE 4: e7549.
23. Ellis RD, Martin LB, Shaffer D, Long CA, Miura K, et al. (2010) Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults. PLoS ONE 5: e8787.
24. Nebie I, Diarra A, Ouedraogo A, Tiono AB, Konate AT, et al. (2009) Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso. Parasite Immunol 31: 474-480.
25. Arisue N, Palacpac NMQ, Tanabe K, Horii T (2011) Clues to Evolution of the SERA Multigene Family in the Genus Plasmodium. In: Friedberg F, editor. Gene Duplication. InTech; ISBN: 978-953-307-387-3. Available: http://www.intechopen.com/books/gene-duplication/clues-to-evolution-of-the-sera-multigene-family-in-the-genus-plasmodium. DOI: 10.5772/23460. Accessed 04 January 2013.
26. van Riet E, Hartgers FC, Yazdanbakhsh M, (2007) Chronic helminth infections induce immunomodulation: consequences and mechanisms. Immunobiology 212: 475-490.
27. Romani L, (2011) Immunity to fungal infections. Nat Rev Immunol 11: 275-288.
28. Esen M, Mordmuller B, de Salazar PM, Adegnika AA, Agnandji ST, et al. (2012) Reduced antibody responses against Plasmodium falciparum vaccine candidate antigens in the presence of Trichuris trichiura. Vaccine 30: 7621-7624.
29. Van Geertruyden JP, Van Eijk E, Yosaatmadja F, Kasongo W, Mulenga M, et al. (2009) The relationship of Plasmodium falciparum humeral immunity with HIV-1 immunosuppression and treatment efficacy in Zambia. Malar J 8: 258.
30. Guinovart C, Aponte JJ, Sacarlal J, Aide P, Leach A, et al. (2009) Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children. PLoS One 4: e5165.